Brought to you by 
Elixir gets North American rights to Kissei's diabetes drug
18 Jul 2006
Executive Summary
Japanese pharma Kissei licensed Elixir (genetics-based research of age-related, metabolic diseases) exclusive development and marketing rights to its Type II diabetes drug Glufast (mitiglinide calcium hydrate; formerly KAD1229) in the US, Canada, and Latin America. Elixir also gets rights to any Glufast combination products that are developed.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com